Deciphera Pharmaceuticals' (DCPH) Neutral Rating Reiterated at Guggenheim

Deciphera Pharmaceuticals (NASDAQ:DCPH - Get Free Report)'s stock had its "neutral" rating reiterated by equities research analysts at Guggenheim in a note issued to investors on Tuesday, Benzinga reports.

Other equities analysts have also recently issued research reports about the company. JPMorgan Chase & Co. boosted their target price on Deciphera Pharmaceuticals from $14.00 to $16.00 and gave the stock a "neutral" rating in a research report on Wednesday, March 20th. Stifel Nicolaus raised their target price on Deciphera Pharmaceuticals from $22.00 to $23.00 and gave the company a "buy" rating in a report on Wednesday, February 7th. Jefferies Financial Group reaffirmed a "hold" rating and set a $25.60 price target (down from $26.00) on shares of Deciphera Pharmaceuticals in a research note on Monday. Barclays upgraded shares of Deciphera Pharmaceuticals from an "underweight" rating to an "equal weight" rating and raised their price objective for the company from $9.00 to $26.00 in a research note on Tuesday. Finally, JMP Securities restated a "market perform" rating on shares of Deciphera Pharmaceuticals in a research report on Tuesday. Six analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $24.17.

Deciphera Pharmaceuticals Stock Down 0.0 %

DCPH stock traded down $0.01 during trading on Tuesday, hitting $25.27. The company had a trading volume of 4,960,319 shares, compared to its average volume of 1,169,447. The firm has a 50-day moving average price of $15.78 and a 200-day moving average price of $14.45. The firm has a market cap of $2.08 billion, a PE ratio of -11.06 and a beta of 0.39. Deciphera Pharmaceuticals has a 1-year low of $9.90 and a 1-year high of $25.40.

Deciphera Pharmaceuticals (NASDAQ:DCPH - Get Free Report) last released its earnings results on Tuesday, February 6th. The company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.58) by $0.04. Deciphera Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 119.33%. The business had revenue of $48.30 million for the quarter, compared to analyst estimates of $45.93 million. During the same quarter in the previous year, the company posted ($0.60) earnings per share. The company's revenue for the quarter was up 32.9% compared to the same quarter last year. Sell-side analysts anticipate that Deciphera Pharmaceuticals will post -2.16 earnings per share for the current year.

Institutional Trading of Deciphera Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. Quest Partners LLC acquired a new stake in shares of Deciphera Pharmaceuticals in the 4th quarter worth about $30,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Deciphera Pharmaceuticals by 96.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 2,026 shares of the company's stock valued at $26,000 after purchasing an additional 997 shares during the period. AJOVista LLC bought a new stake in shares of Deciphera Pharmaceuticals during the fourth quarter valued at approximately $76,000. Exchange Traded Concepts LLC boosted its position in shares of Deciphera Pharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 10,447 shares of the company's stock worth $169,000 after buying an additional 2,649 shares during the period. Finally, Diversified Trust Co bought a new position in Deciphera Pharmaceuticals in the 4th quarter worth approximately $193,000. Institutional investors own 70.96% of the company's stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST.